Literature DB >> 1749008

Choosing the right radionuclide and antibody for intraperitoneal radioimmunotherapy.

S M Larson.   

Abstract

Mesh：

Substances：

Year:  1991        PMID： 1749008     DOI： 10.1093/jnci/83.22.1602

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  3 in total

1.  Results of ovary tumor treatment with abdominally administered (198)Au evaluated on the basis of long term follow up.

Authors:  Mihály Patyánik; Arpád Mayer; István Polgár
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

2.  Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease.

Authors:  Diane E Milenic; Kwamena E Baidoo; Young-Seung Kim; Rachel Barkley; Martin W Brechbiel
Journal:  Dalton Trans       Date:  2017-10-31       Impact factor: 4.390

3.  Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy.

Authors:  D J King; P Antoniw; R J Owens; J R Adair; A M Haines; A P Farnsworth; H Finney; A D Lawson; A Lyons; T S Baker
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.